Gabapentin Inhibits Multiple Steps in the Amyloid Beta Toxicity Cascade

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Oligomeric beta-amyloid peptide (Aβ) is a key neurotoxic agent in Alzheimer's disease (AD).
• Aβ oligomers form pore-like structures on neuronal membranes, disrupting calcium homeostasis and leading to synaptic dysfunction and neuronal death.

Purpose of the Study:

• To identify compounds with neuroprotective effects against Aβ toxicity.
• To investigate the mechanism of action of identified compounds, specifically targeting the C-terminal region of Aβ.

Main Methods:

• Molecular screening to identify compounds targeting the Aβ C-terminal region.
• Assays to measure Aβ peptide aggregation and membrane association.
• Electrophysiological recordings and imaging in hippocampal neurons to assess Aβ-induced toxicity and the effects of gabapentin (GBP).

Main Results:

• Gabapentin (GBP), an FDA-approved drug, was identified as a neuroprotective agent against Aβ toxicity.
• GBP significantly inhibited Aβ aggregation and reduced its association with neuronal membranes.
• GBP antagonized Aβ-induced intracellular calcium dyshomeostasis and synaptotoxicity in hippocampal neurons.

Conclusions:

• Gabapentin (GBP) effectively interferes with multiple steps of Aβ-induced neurotoxicity, demonstrating significant neuroprotective potential.
• GBP's ability to block Aβ aggregation, membrane binding, and downstream toxic effects warrants further investigation in animal models and human clinical trials for Alzheimer's disease.